Prevalence, Awareness, Attitudes and Patterns of Stimulant Drug Use Among Students in Egyptian Universities (SDU)

September 27, 2025 updated by: Asmaa Ahmed Hamed Mohie Eldin

Prevalence, Patterns, Awareness and Attitudes of Stimulant Drug Use Among Students in Egyptian Universities: a Cross-sectional Study.

Stimulants are dangerous drugs that are commonly abused by individuals looking to stay alert and focused, lose weight, stay awake, and get high. Although these drugs can be extremely harmful and even life-threatening, many of them can also be used to treat conditions like ADHD, narcolepsy, and in some cases, depression. There are many types of stimulant drugs, and it can be beneficial to know a little about each one, its purposes, and how harmful it can be when abused.

Illicit stimulants are usually schedule II, depending on whether or not they can be used to treat medical conditions. While some variations of stimulants are schedule I drugs, most are extremely addictive and dangerous schedule II substances. These drugs are often abused in a binge-crash pattern. According to the NIDA Teen, "In order to keep the 'high' going, people may take the drug repeatedly within a short period of time, at increasingly higher doses." This makes these drugs extremely addictive.

The aim of this survey to detect prevalence of non prescription stimulants in Egyptian students and increase their awareness of the harmful effects of these drugs.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Methodology Undergraduate students at a large public university in Egypt (Minia, Assuit, Souhag, South Valley) who were 18 years of age or older took the survey in 2024. All survey and recruitment materials were approved by Minia University, faculty of pharmacy.

Students will receive survey through email. Students took the survey online at a time and location of their choice. No time limit was imposed. Participants will automatically routed through each section of the survey. First, students read a description of the study, including potential benefits and costs of taking the survey, and then they will be asked if they are a current undergraduate student at the participating university and their age. First section included the demographic data of participants, the second section the investigator will aske participants to indicate if they had ever been prescribed a stimulant. If participant answered yes, participants will route to the next section which asks about the frequency of use, the effects of stimulants and any complain if present.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Minya, Egypt, 11666
        • Asmaa Ahmed Hamed

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Undergraduate students at a large public university in Egypt who were 18 years of age or older took the survey in 2024. All survey and recruitment materials were approved by Minia University, faculty of pharmacy.

Students were received survey through email. Students took the survey online at a time and location of their choice. No time limit was imposed.

Description

Inclusion Criteria:

- Academic student Age (18-30) years Included in medical faculty

Exclusion Criteria:

  • Not undergraduates student Aged < 18 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
study group

Undergraduate students at a large public university in Egypt who were 18 years of age or older took the survey in 2024. All survey and recruitment materials were approved by Minia University, faculty of pharmacy.

Students were received survey through email. Students took the survey online at a time and location of their choice.
Other: questionnaire
observational study

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Prevalence/ pattern
Time Frame: 1 year
  • - Do/ did you use stimulants ( Recreational drugs): Yes No
  • How do / did you obtain this medication Prescribed Non prescribed
  • When did you start receiving stimulants for last 1 year for last 3 years for last 5 years

  • Which Stimulant (drug) is/ was used

    • tobacco products (e.g., coffee, chocolate, cigarettes) high caffeine products
    • pseudoephedrine, ( nasal decongestant)
    • methylphenidate [Ritalin]
    • amphetamine [Adderall]
    • methamphetamine
    • modafinil (Provigil)
    • dextroamphetamine (Dexedrine)
    • dextro/levoamphetamine (Adderall)
    • adrafinil (Olmifon)
    • piracetam
    • Others
1 year
Awareness/ attitude
Time Frame: 1 year

- How do you know about the effect of stimulants: Substance use by peers Friends as a source of prescription stimulants Social media Promotion

  • Why do you use stimulant Because it helps me concentrate Because it helps me study and enhance memory Because it helps increase my alertness and concentration Because it gives me a high mood Because it helps me to be more energetic Because it improves sleep quality Because it decreases stress level Because of experimentation Because it helps me lose weight
  • Do you know that stimulant is harmful to the body systems Yes No

  • Which of the following side effects do you experience after using stimulant

    • decreased appetite
    • weight loss
    • headache
    • insomnia
    • dizziness
    • nervousness.
    • Seizures
    • cardiac events (increase blood pressure and heart rate, heart attacks)
    • psychosis
  • Did you receive treatment for the side effects after using stimulants Yes No
1 year

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Demographic data
Time Frame: 1 year

- Age: 18-20 20-22 22-25

- Sex: Male Female

- Residence: Rural Urban

  • University Minia Assiut South Valley Suhag
  • Faculty Pharmacy Medicine
  • Academic Year:

First tear second year Third year fourth year Fifth year

  • Cigarette smoking Yes No
  • Associated disorder:

psychic (e.g. ADHD)

  • income or economic level Low income moderate income high income
  • visits to emergency department or hospital (times/ year) 1-3 4-10 11-15 >15
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Asmaa Ahmed Hamed Mohie Eldin

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 10, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 30, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 30, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 9, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 16, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 17, 2024

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 2, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 27, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • MPEC 240704 (Registry Identifier: Minia University)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Study of Stimulants in Egypt

Clinical Trials on questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings